News archivos - laminarpharma

11 Mar Laminar Pharma Announces first open-label Progression-Free Survival data for LAM561 in combination with standard of Care in First-Line Therapy for Newly Diagnosed Glioblastoma MGMT-methylated patients

Posted at 10:51h in News

Laminar Pharma Announces first open-label Progression-Free Survival data for LAM561 in combination with standard of Care in First-Line Therapy for Newly Diagnosed Glioblastoma MGMT-methylated patients [Palma, March 4th 2025] – Laminar Pharma, a leader in the development of innovative cancer therapy based on membrane lipid therapy,...

17 Jun Last patient in: Laminar Pharmaceuticals S.A. completes recruitment for CLINGLIO, the phase 2b/3 Clinical Trial of idroxioleic acid (LAM561) in combination with RT and TMZ for adults with newly diagnosed glioblastoma.

Posted at 11:38h in News, Press, Uncategorized

140 patients have been recruited at sites in Spain, Italy, France and United Kingdom. The open readout of the trial is expected by late 2024. Laminar aims to submit regulatory filings or conditional marketing authorization by early 2025. Laminar Pharmaceuticals S.A., a clinical-stage biotechnological company developing novel therapies...

06 Mar Laminar Pharmaceuticals S.A. receives recommendation from the Independent Data Monitoring Committee to advance to the next stage of CLINGLIO, the phase 2b/3 Clinical Trial of LAM561 in combination with RT and TMZ for adults with newly diagnosed glioblastoma.

Posted at 08:10h in News, Press, Uncategorized

The independent data monitoring committee (IDMC) has recommended continuation of CLINGLIO without modification after its assessment of LAM561 interim efficacy in newly diagnosed Glioblastoma. This follows the previous recommendation in relation to safety. CLINGLIO remains on track to have its open readout at 66 progression...

11 Sep Laminar Pharma Receives Rare Pediatric Disease Designation from the U.S. FDA for LAM561

Posted at 15:35h in News

Laminar Pharmaceuticals S.A., empresa biotecnológica española en fase clínica centrada en el desarrollo de nuevas terapias para tratar diversas patologías con altas necesidades médicas, se complace en anunciar el reclutamiento de los primeros 45 pacientes en el estudio clínico de fase II/III en glioblastoma de...

10 Aug Hope versus experience in glioblastoma

Posted at 12:44h in Blog, News

Development of new drugs for this hard-to-treat brain cancer is a slow and incremental process....

13 Jul Investment in Spanish biotech is at an all-time high

Posted at 13:18h in Blog, News

The Spanish Bioindustry Association (AseBio), where Laminar Pharma is a member, has published its latest annual report on the state of the biotech sector in Spain, with updated data from 2020. ...

El equipo de Laminar Pharma, con Sonrisa Médica.

05 May Laminar partners with charity Sonrisa Médica to bring joy to hospitalised children

Posted at 15:41h in Blog, News

Laminar Pharma has signed an agreement to sponsor the charity Sonrisa Médica, whose mission is to make hospital stays bearable for children, through laughter and magic....

23 Mar Meet the CEO: Dr. Pablo Escribá

Posted at 17:13h in Blog, News

“If someone has done it before, I can do it too – if no one has done it, I can be the first”: for 30 years, this compass has guided the prolific scientific career of Dr. Pablo Escribá, founder and CEO of Laminar Pharma....

Amparo Navarro, dean of the University of Alicante (UA) and president of the Alicante Science Park Foundation (PCA) and Pablo Escribá, CEO of Laminar Pharmaceuticals, signing the contract.

10 Mar We have joined The Universidad de Alicante Science Park

Posted at 17:09h in News

Alicante Science Park Foundation (PCA) and Laminar Pharmaceuticals have signed today the contract by which the biotechnology company is linked to the PCA....

10 Mar Our researcher Gema Malet receives an individual Marie Skłodowska-Curie grant in recognition for excellent professional development

Posted at 16:50h in News

In 2020, biologist Gema Malet Engra joined our company after a successful 15-year career in fundamental and applied research in Oncology at several international research centers. ...

News